A Study Evaluating TRIV-509 in Atopic Dermatitis
A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-509 in Adults With Moderate to Severe Atopic Dermatitis
Triveni Bio
90 participants
Aug 26, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this interventional study is to learn if TRIV-509 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-509. Participants will receive 4 doses of the study intervention that they are randomized to (TRIV-509 or placebo), and at Week 16 will cross over and receive 4 doses of the other study intervention. The study duration for individual participants is up to 57 weeks, including a Screening period of up to 30 days.
Eligibility
Inclusion Criteria2
- Has Atopic Dermatitis.
- Has moderate to severe, active and symptomatic AD
Exclusion Criteria2
- Severe or uncontrolled medical conditions.
- Use of topical treatments, phototherapy, systemic immunosuppressives or immunomodulatory therapies, or immunomodulatory biologics, within stated washout periods.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
TRIV-509 (Subcutaneous injection)
Drug: Placebo (Matching Placebo subcutaneous injection)
Locations(44)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07167758